Skip to main content
S 1183 115th Congress Senate

FDA Regulatory Efficiency Act

Official title: A bill to establish a third-party quality system assessment program.

Introduced: May 18, 2017 See on congress.gov
Health Administrative law and regulatory proceduresDepartment of Health and Human ServicesDrug safety, medical device, and laboratory regulationFood and Drug Administration (FDA)
More subjectsShow fewer subjects
Health technology, devices, suppliesProduct safety and quality
This bill died when the 115th Congress ended
It never became law before the 115th Congress (2017–2018) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
May 18, 2017
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
May 18, 2017
Introduced in Senate
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Latest action May 18, 2017

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

 Plain-English summary Congressional Research Service

FDA Regulatory Efficiency Act

This bill amends the Federal Food, Drug, and Cosmetic Act to require the Food and Drug Administration (FDA) to establish a third-party quality system assessment program to accredit persons to assess whether a medical device manufacturer's quality system can ensure the safety and effectiveness or substantial equivalence of an approved medical device after certain changes, including changes in manufacturing or changes to enhance device safety.

Device manufacturers with quality systems that have been certified by an accredited person are allowed to make changes to a device without submitting to the FDA the premarket notification, 30-day notice, or premarket approval supplement that would otherwise be required.

An accredited person who assesses a device manufacturer's quality system must submit a summary of their assessment and, as appropriate, a certification of the quality system to the FDA within 30 days of the assessment. An assessment summary and certification is deemed accepted by the FDA 30 days after submission unless the FDA determines that additional information is needed to support certification, the assessment or certification is unwarranted, or an action other than acceptance of the certification is otherwise justified.

Device manufacturers who make changes to devices without submitting a premarket notification must describe the changes in an annual summary submitted to the FDA. Changes made without submitting a 30-day notice or a premarket approval supplement must be described in a periodic report.

Certifications accepted by the FDA remain in effect for two years.

The FDA must report on this quality system assessment program no later than January 31, 2022. The program is terminated at the end of FY2022.
 Related & companion bills 2
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
Cite this page click to expand
APA
U.S. Congress. (2026). S. 1183: FDA Regulatory Efficiency Act. 115th Congress. Open America. https://openamerica.io/bill/115-S-1183/
MLA
"S. 1183: FDA Regulatory Efficiency Act." 115th Congress, 2026, Open America, https://openamerica.io/bill/115-S-1183/.
Bluebook (legal)
S. 1183, 115th Cong. (2026), https://openamerica.io/bill/115-S-1183/.
Markdown link
[S. 1183: FDA Regulatory Efficiency Act](https://openamerica.io/bill/115-S-1183/)
Report a problem